TAK 058
Alternative Names: ENV-8058Latest Information Update: 28 Jan 2019
Price :
$50 *
At a glance
- Originator Envoy Therapeutics
- Developer Takeda
- Class Antidementias; Antipsychotics
- Mechanism of Action Serotonin 3 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Schizophrenia
Most Recent Events
- 28 Jan 2019 No recent reports of development identified for phase-I development in Schizophrenia(Combination therapy) in USA (PO, Liquid)
- 04 Nov 2017 No recent reports of development identified for phase-I development in Schizophrenia(In volunteers) in USA (PO, Liquid)
- 01 Dec 2015 Phase-I clinical trials in Schizophrenia (Combination therapy) in USA (PO)